A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

NCT02640833 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study Stopped

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Non-Hodgkin Lymphoma

Interventions

DRUG: Duvelisib
DRUG: Venetoclax

Sponsor

AbbVie

Collaborators

[object Object]